WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005114173) HDM2-INHIBITOR COMPLEXES AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/114173    International Application No.:    PCT/US2004/012347
Publication Date: 01.12.2005 International Filing Date: 22.04.2004
IPC:
C12Q 1/70 (2006.01), C07K 14/82 (2006.01), C12N 9/64 (2006.01), C12Q 1/68 (2006.01), G01N 31/00 (2006.01), G01N 33/48 (2006.01), G01N 33/50 (2006.01), G01N 33/574 (2006.01), G06F 19/16 (2011.01), G06F 19/18 (2011.01)
Applicants: ORTHO-MCNEIL PHARMACEUTICALS, INC. [US/US]; U.S. Route 202, Raritan, New Jersey 08869 (US) (For All Designated States Except US).
SCHUBERT, Carsten [DE/US]; (US) (For US Only).
GRASBERGER, Bruce [US/US]; (US) (For US Only).
MAGUIRE, Diane [US/US]; (US) (For US Only).
DECKMAN, Ingrid [US/US]; (US) (For US Only).
SPURLINO, John [US/US]; (US) (For US Only)
Inventors: SCHUBERT, Carsten; (US).
GRASBERGER, Bruce; (US).
MAGUIRE, Diane; (US).
DECKMAN, Ingrid; (US).
SPURLINO, John; (US)
Agent: JOHNSON, Philip, S.; One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US)
Priority Data:
Title (EN) HDM2-INHIBITOR COMPLEXES AND USES THEREOF
(FR) COMPLEXES INHIBITEURS HDM2 ET UTILISATIONS DE CEUX-CI
Abstract: front page image
(EN)The present invention includes crystallized HDM2 peptides as well as descriptions of the X-ray diffraction patterns of the crystals. The diffraction patterns allow the three dimensional structure of HDM2 to be determined at atomic resolution so that ligand binding sites on HDM2 can be identified and the interactions of ligands with HDM2 amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MDM2 and HDM2 oncoproteins.
(FR)La présente invention comporte des peptides cristallisés HDM2 de même que des descriptions des motifs de diffraction aux rayons X des cristaux. Les motifs de diffraction permettent de déterminer la structure tridimensionnelle de HDM2 avec une définition atomique de façon à pouvoir identifier les sites de liaison de ligand en HDM2 et modéliser les interactions des ligands avec les résidus d’acide aminé HDM2. Les modèles élaborés à l’aide de ces cartes permettent de concevoir des ligands susceptibles de remplir des fonctions d’agents actifs comme par exemple, mais sans s’y limiter, une fonction inhibitrice d’oncoprotéines MDM2 et HDM2.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)